Overview

Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors

Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This is a single-center trial in subjects with pancreatic cancer and other advanced solid tumors. It is an open-label, single arm dose escalation Phase IB trial with subjects accrued in a 3 subject dose escalation cohort. Subjects with treated advanced solid tumors, and showing disease progression on established standard therapy, will be enrolled in this trial.
Phase:
Phase 1
Details
Lead Sponsor:
Danae Hamouda
John Nemunaitis, MD
Treatments:
Digoxin
Metformin
Simvastatin